A case of hemophagocytic lymphohistiocytosis in a hemodialysis patient with coronavirus disease 2019
Abstract During the treatment of a patient on hemodialysis with severe coronavirus disease 2019 (COVID-19), the patient was weaned from extracorporeal membrane oxygenation, which was used to treat severe COVID-19 pneumonia. However, the patient’s condition worsened after the peak infection phase of COVID-19 because of acute respiratory distress syndrome with suspected hemophagocytic lymphohistiocytosis (HLH). After a bone marrow biopsy confirmed the diagnosis, methylprednisolone pulse therapy, followed by combination therapy (including oral prednisolone and cyclosporine) was immediately administered, and the patient survived. Because HLH can occur a month or more after the onset of COVID-19, even if the viral load is reduced to the point of being undetectable by reverse transcriptase-polymerase chain reaction, it can be considered to correspond to the “post-acute COVID-19 syndrome,” which has recently been proposed. Early intervention is necessary, because HLH can be fatal. Therefore, it is important to know that HLH can occur at any stage of COVID-19 and to pay attention to the patient’s progress over time, including checking the HScore..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
CEN Case Reports - 12(2023), 4 vom: 03. März, Seite 390-396 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kaneko, Satoru [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
COVID-19 |
---|
Anmerkungen: |
© The Author(s) under exclusive licence to The Japan Society of Nephrology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
---|
doi: |
10.1007/s13730-023-00776-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR053604032 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | SPR053604032 | ||
003 | DE-627 | ||
005 | 20231102064640.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231102s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s13730-023-00776-9 |2 doi | |
035 | |a (DE-627)SPR053604032 | ||
035 | |a (SPR)s13730-023-00776-9-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kaneko, Satoru |e verfasserin |4 aut | |
245 | 1 | 2 | |a A case of hemophagocytic lymphohistiocytosis in a hemodialysis patient with coronavirus disease 2019 |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) under exclusive licence to The Japan Society of Nephrology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
520 | |a Abstract During the treatment of a patient on hemodialysis with severe coronavirus disease 2019 (COVID-19), the patient was weaned from extracorporeal membrane oxygenation, which was used to treat severe COVID-19 pneumonia. However, the patient’s condition worsened after the peak infection phase of COVID-19 because of acute respiratory distress syndrome with suspected hemophagocytic lymphohistiocytosis (HLH). After a bone marrow biopsy confirmed the diagnosis, methylprednisolone pulse therapy, followed by combination therapy (including oral prednisolone and cyclosporine) was immediately administered, and the patient survived. Because HLH can occur a month or more after the onset of COVID-19, even if the viral load is reduced to the point of being undetectable by reverse transcriptase-polymerase chain reaction, it can be considered to correspond to the “post-acute COVID-19 syndrome,” which has recently been proposed. Early intervention is necessary, because HLH can be fatal. Therefore, it is important to know that HLH can occur at any stage of COVID-19 and to pay attention to the patient’s progress over time, including checking the HScore. | ||
650 | 4 | |a Hemophagocytic lymphohistiocytosis |7 (dpeaa)DE-He213 | |
650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Hemophagocytic syndrome |7 (dpeaa)DE-He213 | |
650 | 4 | |a HScore |7 (dpeaa)DE-He213 | |
700 | 1 | |a Inoue, Tsutomu |4 aut | |
700 | 1 | |a Tarumoto, Norihito |4 aut | |
700 | 1 | |a Haga, Yoshiyuki |4 aut | |
700 | 1 | |a Yokota, Kazuhiro |4 aut | |
700 | 1 | |a Yamaguchi, Hiroshi |4 aut | |
700 | 1 | |a Okada, Hirokazu |0 (orcid)0000-0002-1839-9078 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t CEN Case Reports |d Tokyo : Springer Japan, 2012 |g 12(2023), 4 vom: 03. März, Seite 390-396 |w (DE-627)SPR032206895 |w (DE-600)2660492-9 |x 2192-4449 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2023 |g number:4 |g day:03 |g month:03 |g pages:390-396 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13730-023-00776-9 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
951 | |a AR | ||
952 | |d 12 |j 2023 |e 4 |b 03 |c 03 |h 390-396 |